Antiphospholipid syndrome in lupus retinopathy

10Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease that can affect any part of the human body including the eyes. Common blinding ocular manifestations include central retinal artery occlusion (CRAO), central retinal vein occlusion (CRVO), severe vaso-occlusive retinopathy, and optic nerve involvement. Antiphospholipid syndrome (APS) in lupus is usually associated with large vessel occlusions and needs prompt treatment with anticoagulant. We are reporting two cases of APS in SLE patients that presented with CRVO (case 1) and vaso-occlusive lupus retinopathy (case 2). Both cases were positive for antiphospholipid antibody (APA) and were treated with immunosuppression, anticoagulant, and laser treatment. Thus, screening for APA is vital in SLE patients with lupus retinopathy, as prompt treatment with anticoagulants is important to prevent further vascular thrombosis, which worsens the visual prognosis.

Cite

CITATION STYLE

APA

Hong-Kee, N., Mei-Fong, C., Azhany, Y., & Zunaina, E. (2014). Antiphospholipid syndrome in lupus retinopathy. Clinical Ophthalmology, 8, 2359–2363. https://doi.org/10.2147/OPTH.S71712

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free